Clinical Trials List
2023-09-01 - 2028-12-31
Phase III
Not yet recruiting2
Recruiting1
ICD-10C82.50
Diffuse follicle center lymphoma, unspecified site
ICD-10C82.59
Diffuse follicle center lymphoma, extranodal and solid organ sites
ICD-10C83.10
Mantle cell lymphoma, unspecified site
ICD-10C83.19
Mantle cell lymphoma, extranodal and solid organ sites
ICD-10C83.30
Diffuse large B-cell lymphoma, unspecified site
ICD-10C83.39
Diffuse large B-cell lymphoma, extranodal and solid organ sites
ICD-10C83.80
Other non-follicular lymphoma, unspecified site
ICD-10C83.89
Other non-follicular lymphoma, extranodal and solid organ sites
ICD-10C84.90
Mature T/NK-cell lymphomas, unspecified, unspecified site
ICD-10C84.99
Mature T/NK-cell lymphomas, unspecified, extranodal and solid organ sites
ICD-10C84.A0
Cutaneous T-cell lymphoma, unspecified, unspecified site
ICD-10C84.A9
Cutaneous T-cell lymphoma, unspecified, extranodal and solid organ sites
ICD-10C84.Z0
Other mature T/NK-cell lymphomas, unspecified site
ICD-10C84.Z9
Other mature T/NK-cell lymphomas, extranodal and solid organ sites
ICD-10C85.10
Unspecified B-cell lymphoma, unspecified site
ICD-10C85.19
Unspecified B-cell lymphoma, extranodal and solid organ sites
ICD-10C85.20
Mediastinal (thymic) large B-cell lymphoma, unspecified site
ICD-10C85.29
Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites
ICD-10C85.80
Other specified types of non-Hodgkin lymphoma, unspecified site
ICD-10C85.89
Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites
ICD-10C85.90
Non-Hodgkin lymphoma, unspecified, unspecified site
ICD-10C85.99
Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites
ICD-10C86.4
Blastic NK-cell lymphoma
ICD-10C88.4
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9202.80
Other lymphomas, unspecified, extranodal solid organ sites
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Chieh-Lung Cheng Division of General Internal Medicine
- YAO CHI-YUAN Division of General Internal Medicine
- - - Division of General Internal Medicine
- CHENG-HONG TSAI Division of General Internal Medicine
- Tai-Chung Huang Division of General Internal Medicine
- 袁章祖 Division of Others
- 田豐銘 Division of General Internal Medicine
- MING YAO Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 王元欽 Division of Hematology & Oncology
- Ming-Chung Kao Division of Hematology & Oncology
- 高小雯 Division of Hematology & Oncology
- 林潔 Division of Nuclear Medicine
- 陳建誠 Division of Radiology
- HSUAN JEN SHIH Division of Hematology & Oncology
- Tung-Liang Lin Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Chia-Jen Liu Division of Hematology & Oncology
- Ting-An Lin Division of Hematology & Oncology
- 陳蓉宣 Division of Radiology
- Hao-Yuan Wang Division of Hematology & Oncology
- 陳玟均 Division of Hematology & Oncology
- Yao-Chung Liu Division of Hematology & Oncology
- 蔡淳光 Division of Hematology & Oncology
- Po-Shen Ko Division of Hematology & Oncology
- Sheng-Hsuan Chien Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
10 participants
-
Global
182 participants
